Seeking Alpha

In response to an aging global population (and possibly in an effort to replace lost Copaxone...

In response to an aging global population (and possibly in an effort to replace lost Copaxone revenue), Teva (TEVA +2%) is investing $15M over five years in the development of new treatments for diseases such as Alzheimer's, Huntington's, and Parkinson's. "I am convinced that this effort will yield not just one or two drugs but will yield a great understanding how the brain works," CEO Jeremy Levin says. (PR, Reuters)
From other sites
Comments (4)
  • Freudo1
    , contributor
    Comments (36) | Send Message
     
    This is an excellent proactive move for Teva. Alzheimer's is an expensive medical problem in the United States.Genetic and stem
    cell research may prove to be the best strategy.
    23 Jul 2013, 01:09 PM Reply Like
  • Joe Dirnfeld
    , contributor
    Comments (1128) | Send Message
     
    $ 15 million is going to concur those diseases, on the cheap. Good luck.
    23 Jul 2013, 01:09 PM Reply Like
  • moseslarsen
    , contributor
    Comments (481) | Send Message
     
    We have been eagerly awaiting some forward looking statements from Levin. Long TEVA. Moses
    23 Jul 2013, 01:52 PM Reply Like
  • mrcsn
    , contributor
    Comments (10) | Send Message
     
    Good PR from TEVA. 3 million a year is not significant funding for basic research.
    23 Jul 2013, 09:04 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs